Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review, we described the evidence of the IL-6 response in patients with COVID-19, clarified the pathogenesis of the role of IL-6-mediated CRS in severe COVID-19, and highlighted the rationale for the use of anti-IL-6 agents and key information regarding the potential features of these IL-6 inhibitors in COVID-19 patients.
【저자키워드】 COVID-19, interleukin-6, Cytokine release syndrome, interleukin-6 inhibitor., 【초록키워드】 coronavirus disease, pathology, Coronavirus disease 2019, Pathogenesis, severe COVID-19, Tocilizumab, Therapeutics, IL-6, interleukin-6, sarilumab, cytokine, Case report, Cytokine release syndrome, interleukin, information, COVID-19 patients, IL-6 inhibitor, CRS, Signaling, Evidence, IL-6 inhibitors, siltuximab, evidence of, (Tocilizumab, severe coronavirus disease, rationale, syndrome, severe COVID-19 patients, trans, key factor, triggering, feature, effective, anti-IL-6, described, classical, appear, inhibiting, patients with COVID-19, severe COVID-19 patient, 【제목키워드】 Treatment, IL-6 inhibitor, role,